Wed, December 11, 2024
Tue, December 10, 2024
[ Tue, Dec 10th 2024 ]: The New Yorker
The Dawn of the Bionic Man
[ Tue, Dec 10th 2024 ]: Mercury News
California News
[ Tue, Dec 10th 2024 ]: ABC News
Entertainment News
Mon, December 9, 2024
[ Mon, Dec 09th 2024 ]: BBC
Beds, Herts & Bucks
[ Mon, Dec 09th 2024 ]: Uproxx
The Best TV Shows Of 2024
[ Mon, Dec 09th 2024 ]: Paste
The 25 Best PC Games of 2024
[ Mon, Dec 09th 2024 ]: CNET
Top News Stories
Sun, December 8, 2024
Sat, December 7, 2024
[ Sat, Dec 07th 2024 ]: Newsweek
Russia-Ukraine War
[ Sat, Dec 07th 2024 ]: imdb.com
Canada's 30 Funniest TV Shows
[ Sat, Dec 07th 2024 ]: Daily Mail
UK Celebrity News
[ Sat, Dec 07th 2024 ]: Food Safety News
Food Safety News
Fri, December 6, 2024
[ Fri, Dec 06th 2024 ]: Graphic
Latest Ghana News Headlines Today
[ Fri, Dec 06th 2024 ]: The Columbian
Clark County News
[ Fri, Dec 06th 2024 ]: who13
Cyclones react to 10 wins
[ Fri, Dec 06th 2024 ]: TravelPulse
Hotels and Resorts News
[ Fri, Dec 06th 2024 ]: Business Standard
Share Market Today
[ Fri, Dec 06th 2024 ]: Reuters
Aerospace & Defense
Thu, December 5, 2024
[ Thu, Dec 05th 2024 ]: Interest
All news stories
[ Thu, Dec 05th 2024 ]: Paste
The 30 Best TV Shows of 2024
[ Thu, Dec 05th 2024 ]: Phil Bruner
Featured News Stories
[ Thu, Dec 05th 2024 ]: Phil Bruner
Swattie Survival Guide
Wed, December 4, 2024
[ Wed, Dec 04th 2024 ]: Phil Bruner
California News
[ Wed, Dec 04th 2024 ]: Phil Bruner
President Joe Biden
Tue, December 3, 2024
[ Tue, Dec 03rd 2024 ]: Phil Bruner
The 40 Best Games of 2024
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Boku No Roblox Codes
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Yonhap News Agency
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Beds, Herts & Bucks
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Transfer news and rumors
Mon, December 2, 2024
[ Mon, Dec 02nd 2024 ]: Phil Bruner
Watch Samaa News Live
[ Mon, Dec 02nd 2024 ]: Phil Bruner
UK Celebrity News
[ Mon, Dec 02nd 2024 ]: Phil Bruner
The 100 Best Albums of 2024
[ Mon, Dec 02nd 2024 ]: Phil Bruner
From the Newspaper
[ Mon, Dec 02nd 2024 ]: Phil Bruner
South Australia
[ Mon, Dec 02nd 2024 ]: Phil Bruner
Whanganui Chronicle
Sun, December 1, 2024
[ Sun, Dec 01st 2024 ]: Phil Bruner
Wildlife Oddities of the Week
Sat, November 30, 2024
Fri, November 29, 2024
[ Fri, Nov 29th 2024 ]: Phil Bruner
Hotels and Resorts News
[ Fri, Nov 29th 2024 ]: Phil Bruner
The Best Jokes of 2024
Thu, November 28, 2024
[ Thu, Nov 28th 2024 ]: Phil Bruner
Climate and Environment
[ Thu, Nov 28th 2024 ]: Phil Bruner
December 2024 Issue
Wed, November 27, 2024
[ Wed, Nov 27th 2024 ]: Phil Bruner
Decoding Gen Z's content diet
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ]: Phil Bruner
Illustrated Humor in the News
[ Tue, Nov 26th 2024 ]: Phil Bruner
World News
[ Tue, Nov 26th 2024 ]: Phil Bruner
Alexandra Petri
Mon, November 25, 2024
[ Mon, Nov 25th 2024 ]: Phil Bruner
All Kent news
Sun, November 24, 2024
Mon, December 15, 2008
[ Mon, Dec 15th 2008 ]: Market Wire
fasdfasddva s gfg h

Celldex Therapeutics Presents Safety and Immunogenicity Data on CDX-1401 at the International Society of Biological Therapy of

  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. ernational-society-of-biological-therapy-of.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

- Click to Lock Slider

NEEDHAM, Mass.--([ BUSINESS WIRE ])--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the Company presented initial clinical data on CDX-1401 at the 25th Annual Meeting of the International Society of Biological Therapy of Cancer (iSBTc)in Washington, DC. CDX-1401 is a novel antibody-based targeted cancer vaccine candidate being evaluated as a treatment for patients with melanoma and other cancers that are known to express the tumor antigen NY-ESO-1.

"The initial data from this ongoing study confirm safety and immunogenicity even in patients with advanced cancer who have received multiple prior therapies. CDX-1401 has passed the initial Phase 1 hurdles and we look forward to forthcoming cohorts that will include additional TLR agonists in combination regimens."

The data presented were from a Phase 1/2 dose-escalating clinical trial evaluating three different doses of the vaccine in combination with resiquimod , which is an activator of toll-like receptors 7 and 8 (TLR7/8) and stimulator of immune cells. The study has enrolled 20 patients with advanced cancer, of which 35% had confirmed NY-ESO-1 expression. Six patients maintained stable disease and were eligible for multiple cycles of the treatment regimen, including 4 patients who have received 3 or more cycles (6 weeks of treatment followed by a 6 week rest), with stable disease of up to 11.5+ months. The treatment was well tolerated and there were no dose-limiting toxicities. Robust anti-NY-ESO-1 immunity was induced with the majority of the patients developing anti-NY-ESO-1 antibody responses and 39% of the patients having increases in NY-ESO-1 specific T cell responses, including both CD4 and CD8 responses. Importantly, the T cell responses were directed against multiple regions of the NY-ESO-1 antigen.

aCDX-1401 represents a new generation of off-the-shelf dendritic cell targeted vaccines built upon excellent preclinical activity data,a said Tom Davis, M.D., Chief Medical Officer of Celldex Therapeutics. aThe initial data from this ongoing study confirm safety and immunogenicity even in patients with advanced cancer who have received multiple prior therapies. CDX-1401 has passed the initial Phase 1 hurdles and we look forward to forthcoming cohorts that will include additional TLR agonists in combination regimens.a

The CDX-1401 study is continuing to enroll patients to additional cohorts that include combination with poly-ICLC (Hiltonola"), a potent TLR3 agonist and stimulator of immune cells. The study is currently being conducted at multiple centers including Yale Cancer Center, Henry Ford Hospital and Medical Group, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College.

About the CDX-1401 Vaccine

CDX-1401 is a cancer vaccine designed to activate the patienta�s immune system against cancers that express the tumor marker, NY-ESO-1. The product consists of a fully human monoclonal antibody with specificity for the dendritic cell receptor, DEC-205, genetically linked to the NY-ESO-1 tumor antigen. Celldex has accessed NY-ESO-1 through a multi-year clinical research collaboration with the international Ludwig Institute for Cancer Research. By selectively delivering the NY-ESO-1 antigen to dendritic cells in the body, this product is intended to induce robust immune responses against the antigen-expressing cancer cells.

About Celldex Therapeutics, Inc.

Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldexa�s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. For more information, please visit [ http://www.celldextherapeutics.com ].

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Thisrelease contains aforward-looking statementsa made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Companya�s strategic focus and the future development and commercialization (by Celldex and others) of rindopepimut (CDX-110), CDX-1307, CDX-011, CDX-1135 (formerly TP10), CDX-1401, Belinostat, Rotarix� and other products. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties,including, but not limited to, our ability to obtain additional capital on acceptable terms, or at all; our ability to adapt APC Targeting TechnologyTM to develop new, safe and effective vaccines against oncology and infectious disease indications; our ability to successfullycomplete product research and further development of our programs; our development partnersa� willingness to make announcements with respect to co-developed products; the uncertainties inherent in clinical testing; our ability to manage research and development efforts for multiple products at varying stages of development; our strategy and business plans concerning the continued development and commercialization of rindopepimut (PF-04948568 or CDX-110); our ability to successfully complete the transition of Rindopepimut from Pfizer to Celldex; the uncertainties of any future payments with respect to Belinostat, as the development and commercialization of Belinostat is completely outside of Celldex's control; the uncertainties of any future royalty payments with respect to Rotarix�, as the commercialization of Rotarix� is completely outside of Celldex's control; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Companya�s intellectual property; the loss of any executive officers or key personnel or consultants; our ability to successfully integrate the businesses, multiple technologies and programs of CuraGen and Celldex; competition; changes in the regulatory landscape or the imposition of regulations that affect the Companya�s products; and other factors listed under aRisk Factorsa in our annual report on Form 10-K.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.